Pharmaceutical

Lilly sues to block copy of Evista osteoporosis drug

May 5, 2010
Bloomberg News
Watson Pharmaceuticals filed for FDA approval to sell a low-cost version of Eli Lilly and Co.'s osteoporosis medicine. Indianapolis-based Lilly is seeking a court order that would block approval until three of its patents expire in 2017.
More

Closing of Purdue's Chao Center is setback for BioCrossroads

May 1, 2010
J.K. Wall
The university is hoping to find a private company to take over the 5-year-old facility, which formulated and manufactured small batches of drugs used in clinical trials.
More

Medco Health profits climb as it adds big clients

April 28, 2010
 IBJ Staff and Associated Press
Medco, which operates a major pharmacy and distribution center in Whitestown, got a boost from higher prices on brand-name drugs and from greater sales of more profitable generic drugs.
More

Chao exit hurts drug development industry

April 28, 2010
J.K. Wall
Purdue University’s decision to close the Chao Center in West Lafayette is a setback for Indiana’s effort to grow a vibrant contract drug manufacturing sector. But it’s just the latest in a series of unexpected changes—not all for the worse—since Indianapolis-based BioCrossroads launched a contract drug manufacturing initiative in late 2007.
More

Harlan Labs names new CEO

April 23, 2010
 IBJ Staff
The Indianapolis-based provider of clinical research animals has promoted senior manager Hans Thunem to its top spot.
More

Drug prices rise ahead of rebates

April 21, 2010
J.K. Wall
Drug prices rose faster last year than they have in a decade—just in time for big rebates the drug industry promised as part of the health reform law.
More

Lilly to pay $400M to repurchase Cymbalta rights

April 19, 2010
Bloomberg News
Eli Lilly and Co. will repurchase rights to develop and market antidepressant Cymbalta outside the U.S. and Japan from European partner Boehringer Ingelheim for an initial payment of $400 million.
More

Lilly diabetes drug may have cancer risk, FDA says

April 9, 2010
 IBJ Staff and Bloomberg News
Once-weekly form of Byetta is awaiting the FDA's OK. Analyst predict the new version of the drug, if approved, could rack up sales of $2 billion annually.
More

Louisiana gets $20M in Lilly drug settlement

April 7, 2010
Associated Press
Louisiana was one of 13 states that filed individual suits in state courts over allegations that Lilly pushed Zyprexa for uses that had not been approved by federal regulators.
More

Lilly wins court ban on generic copy of Gemzar

April 1, 2010
Bloomberg News, Associated Press
Eli Lilly and Co. won a U.S. court ruling Wednesday that bars Teva Pharmaceutical Industries Ltd. from selling a generic version of the cancer drug Gemzar until November.
More

Lilly drug wins U.K. backing as cancer therapy

April 1, 2010
Bloomberg News
Eli Lilly and Co.'s Alimta has received the preliminary backing of a United Kingdom agency as a maintenance treatment for patients with the most common form of lung cancer.
More

Lilly to let 115 workers go in new outsourcing deal

March 26, 2010
J.K. Wall
Deal with unit of Massachusetts-based Thermo Fisher Scientific would keep many of the employees working in same location.
More

Lilly sues Hospira over generic version of Gemzar

March 24, 2010
Bloomberg News
Indianapolis-based Eli Lilly and Co. sued rival drugmaker Hospira Inc. to prevent it from selling a generic version of the cancer drug Gemzar before a patent on the medicine expires in 2013.
More

Ariad loses $65M patent appeal against Eli Lilly

March 22, 2010
Bloomberg News
Monday's decision throws out a $65.2 million patent-infringement verdict won by Ariad for royalties on Lilly's osteoporosis drug Evista and sepsis medicine Xigris.
More

Bill kicks off years of change for local health care players

March 22, 2010
J.K. Wall
Sweeping changes phase in slowly for most, but insurers, hospitals, drug companies, employers, workers, medical device makers and more will eventually feel impact.
More

Reform offers risk, opportunities for Lilly, WellPoint

March 22, 2010
 IBJ Staff and Bloomberg News
Drugmakers and insurers could gain millions of customers under the legislation, but the industry also will pay new fees and face stricter rules that may shrink profit and fuel mergers.
More

Lilly sues to block generic of Adcirca lung treatment

March 17, 2010
Bloomberg News
Netherlands-based Synthon Pharmaceuticals is seeking U.S. Food and Drug Administration approval to sell a copy of the medicine.
More

Lilly victim of theft from Connecticut warehouse

March 16, 2010
 IBJ Staff and Associated Press
Pharmaceuticals stolen Sunday morning could be worth up to $75 million.
More

Lilly pays $50M-plus for rights to testosterone lotion

March 16, 2010
Bloomberg News
Indianapolis-based Lilly will pay Acrux of West Melbourne, Australia, a $50 million license fee, plus $3 million when manufacturing assets are transferred, but the deal could be worth millions more.
More

FDA says 'not yet' on Lilly's once-weekly Byetta

March 15, 2010
J.K. Wall
Regulators won't require more time-consuming tests of the drug, but want Eli Lilly and Co. and its partners to clarify labeling, manufacturing processes.
More

Cornelius to retire as Bristol-Myers Squibb CEO

March 3, 2010
 IBJ Staff and Associated Press
The former Guidant Corp. CEO and long-time Eli Lilly exec said he and his family will be returning to Indianapolis.
More

Obama health reform plan slaps drugmakers

February 24, 2010
J.K. Wall
Drugmakers, such as Indianapolis-based Eli Lilly and Co., would shoulder $3.3 billion in fees, face ban on pay-for-delay deals with generic competitor.
More

Medco profit rises as mail-order generics business grows

February 23, 2010
 IBJ Staff and Bloomberg News
The pharmacy benefits manager, which has major operations in Whitestown, said fourth quarter profit rose 24 percent.
More

Lilly, Merck, Pfizer starting research center

February 23, 2010
Associated Press
Three major U.S. drugmakers said they have formed a not-for-profit company in Asia to focus on cancer research and treatments.
More

Obama endorses new taxes, more drugmaker fees

February 22, 2010
Bloomberg News
Obama, seeking to break an impasse over health-care legislation, proposes a plan that includes the first Medicare tax on unearned income such as capital gains and higher fees on drugmakers.
More
Page  << 11 12 13 14 15 16 17 18 19 >> pager
Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. These liberals are out of control. They want to drive our economy into the ground and double and triple our electric bills. Sierra Club, stay out of Indy!

  2. These activist liberal judges have gotten out of control. Thankfully we have a sensible supreme court that overturns their absurd rulings!

  3. Maybe they shouldn't be throwing money at the IRL or whatever they call it now. Probably should save that money for actual operations.

  4. For you central Indiana folks that don't know what a good pizza is, Aurelio's will take care of that. There are some good pizza places in central Indiana but nothing like this!!!

  5. I am troubled with this whole string of comments as I am not sure anyone pointed out that many of the "high paying" positions have been eliminated identified by asterisks as of fiscal year 2012. That indicates to me that the hospitals are making responsible yet difficult decisions and eliminating heavy paying positions. To make this more problematic, we have created a society of "entitlement" where individuals believe they should receive free services at no cost to them. I have yet to get a house repair done at no cost nor have I taken my car that is out of warranty for repair for free repair expecting the government to pay for it even though it is the second largest investment one makes in their life besides purchasing a home. Yet, we continue to hear verbal and aggressive abuse from the consumer who expects free services and have to reward them as a result of HCAHPS surveys which we have no influence over as it is 3rd party required by CMS. Peel the onion and get to the root of the problem...you will find that society has created the problem and our current political landscape and not the people who were fortunate to lead healthcare in the right direction before becoming distorted. As a side note, I had a friend sit in an ED in Canada for nearly two days prior to being evaluated and then finally...3 months later got a CT of the head. You pay for what you get...

ADVERTISEMENT